Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...

Genevant Sciences and Arbutus Biopharma have expanded their patent litigation against Moderna internationally, targeting its lipid nanoparticle technology, which could impact products like ...

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax ® and, where applicable, additional Moderna products that Moderna ... company with world-class platforms, a robust ...

The companies specifically claim that Moderna uses their patented lipid nanoparticle (LNP) delivery technology, which is key to ensuring mRNA doesn’t degrade in the body, in its COVID-19 vaccine ...

According to court documents, the lawsuits focus on Moderna's use of lipid nanoparticle encapsulation of mRNA vaccines, a technology used to protect the mRNA molecules as they are delivered to ...

Second, and again despite having many different options, Pfizer and BioNTech copied Moderna's approach to encode for the full-length spike protein in a lipid nanoparticle formulation for a ...

March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ... against Moderna, Inc. and certain ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products ... a robust lipid nanoparticle (LNP) patent portfolio ...